T细胞受体（TCR）识别肿瘤相关抗原（TAAs）的能力是转移性肿瘤浸润淋巴细胞T细胞（TIL）的关键推动因素，可以是一种高效的肿瘤免疫疗法。虽然众所周知TCR具有交叉反应性，可以结合多个不同的肽抗原，但这通常被认为是TCR疗法的不可取的特性和限制。在最近发表于《Cell》杂志的一篇文章中，Dolton和同事发现从用于治疗黑色素瘤的TIL中分离出的某些TCR具有有益的交叉反应性，可以识别多个TAAs（1）。此外，他们阐明TCR交叉反应性在癌细胞根除上的累积价值及其对靶向性癌症免疫疗法的潜在优势。

The ability of T cell receptors (TCR) to recognize tumor associated antigens (TAAs) is a key driver of adoptive transfer of tumor infiltrating lymphocyte T cells (TIL), which can be a highly effective cancer immunotherapy. While it is common knowledge that TCRs are cross-reactive and can bind multiple different peptide antigens, this is typically considered an unattractive feature and limitation for TCR-based therapies. In a recent publication in Cell, Dolton and colleagues discover that certain TCRs, isolated from TILs used for successful treatment of melanoma, possesses beneficial cross-reactivity by recognizing multiple TAA (1). Moreover, they elucidate the cumulative value of TCR cross-reactivity on cancer cell eradication and its prospective advantages for targeted cancer immunotherapies.